Posts Tagged real world evidence

Benchmarking Survey: Can we reduce procurement time in HEOR & RWE?

As healthcare moves towards an increased focus on outcomes and value, health economics & outcomes research (HEOR) and real-world evidence (RWE) are being used to guide value-based decisions, improve outcomes, reduce costs, and achieve market access. This move toward new ways of defining value has led to growth in the number and complexity of HEOR and RWE initiatives as well as increased diversity in the types of stakeholders involved in them.

Outsourcing of HEOR & RWE is increasing

As a result of expansion in HEOR/RWE initiatives, many companies are outsourcing to keep up. A 2017 survey conducted by ISR Reports found that companies outsource an average of 75% of their HEOR work, a trend driven by limited internal resources, lack of time, and the need to foster great credibility by using trusted third-party partners.1

To better understand the challenges and opportunities in the procurement and contracting of HEOR/RWE projects, HealthEconomics.Com and Scientist.com conducted an online survey of researchers and suppliers in HEOR, RWE and related areas with over 150 respondents. The HEOR and RWE Sourcing and Procurement Challenges and Opportunities Benchmarking Survey represented a wide variety of companies including biopharma/medical device (35%), research consultancies including CROs (37%), private payers/pharmacy benefit management companies (5%), and academia (7%). Forty percent of respondents were from large organizations with 1,000 or more employees. About one-third (31%) categorized themselves as a buyer of services, 38% were a supplier, and 25% were both a buyer and a supplier. 


Consistent with the ISR survey1, the HealthEconomics.Com and Scientist.com benchmarking survey showed that three-fourths (71%) of respondents outsource one-half or more of their work.

Contracting time is a challenge in HEOR & RWE procurement

One of the most serious stumbling blocks identified was long contracting times.

More than one-half (55%) of HEOR/RWE professionals found that average contracting time exceeded 2 months and 10% found that it exceeded 6 months.

Consequences of long contracting time

Long contracting times delay insights, impede market access, hinder decision-making by providers and payers, and may result in increased costs of drug development and commercialization. Ultimately, this leads to delays in how quickly an intervention gets to the patient. As one Medical Affairs professional from a consulting company put it: “[Procurement] takes a very long time, making [study] results less meaningful”.

Need for standardization

Many respondents grappled with overly complex administrative and legal processes during the HEOR/RWE sourcing and procurement process. Eighty percent of respondents (both buyers and suppliers) agreed that buyer requirements are not standardized. This finding was echoed by an editorial in Clinical Leader, stating, “HEOR procurement can be intricate due to the lack of standardized requirements and regulations.”2 This results in a longer period in the negotiation and set up phase of contracting before the actual work can even begin.

While both suppliers and buyers identified a more standardized and expedited contracting process as a major need, there were key differences in how their comments approached the issue.

Suppliers focused on problems with buyer processes with 8 out of 10 agreeing that it is difficult to navigate through the buyer’s procurement process. Seventy percent agreed that buyer compliance requirements hinder successful contracting.

Buyers focused on the time spent working with their own internal procurement team. A Director of Outcomes Research from a pharmaceutical company said that, “…timelines certainly are [affected] when having to jump through hoops to demonstrate why one supplier is needed over another”. Indeed, over 60% agreed that it is challenging to compare suppliers for a project.

A solution that simplifies administrative and legal requirements while allowing buyers to easily differentiate suppliers is clearly needed.

A marketplace solution for sourcing challenges

Scientist.Com, the world’s leader in scientific services marketplaces connecting buyers and suppliers, found that an online marketplace approach improved contracting time and saved money. As shown in the figure below, the online marketplace resulted in a first proposal within 7 days of a highly complex request, provided for easy comparison of 5 different suppliers, and resulted in a realized cost savings of >$20,000. Applying this approach to HEOR and RWE could result in a similarly expedited contracting process and the potential for cost savings.

Figure: Impact of Online Marketplace on Supplier Response Time and Costs
[source: Scientist.Com data on file]

HealthEconomics.Com and Scientist.com have partnered together to launch the HEOR & RWE Marketplace, an online solution that accelerates the sourcing and procurement process for researchers and suppliers of HEOR, RWE and market access services.3 By streamlining the process for buyers and sellers, the HEOR & RWE Marketplace will deliver reduced time to contract, quicker time to insight, and faster market access, while saving costs.

The HEOR & RWE Marketplace

Powered by two trusted life science brands

The HEOR & RWE Marketplace is comprised of a global network of suppliers with access to a host of data sources, and placing an order is simple:

  • Researcher places a request
  • The details of the request are sent to several qualified suppliers
  • Researcher receives responses within days
  • An experienced Research ConciergeTM team quickly narrows the pool of eligible suppliers
  • Researcher receives proposals to compare
  • Researcher selects the best one for the particular study
  • Researcher receives requested services upon internal approval and completed PO

As HEOR and RWE are increasingly required by payers and providers, outsourcing and procurement are critically important to the research process of evidence development. It is imperative that administrative, sourcing, and legal hurdles do not prevent much needed interventions from reaching patients. Solutions like a marketplace approach should be fully evaluated in terms of their ability to simplify procurement, reduce time to contract, deliver quicker time to insight and facilitate faster market access, while saving costs.


References:

  1. ISR Reports. Benchmarking the Pharma Industry’s HEOR Function. (2017). Available at: https://www.isrreports.com/wp-content/uploads/woocommerce_uploads/2017/09/2017-Benchmarking-the-Pharma-Industrys-HEOR-Function-2nd-Edition-Enterprise.pdf.
  2. Parikh, H. An Overview Of Offshoring HEOR. Clinical Leader (2015). Available at: https://www.clinicalleader.com/doc/an-overview-of-offshoring-heor-0001.
  3. HealthEconomics.Com, Scientist.Com Partner on RWE/HEOR Initiative. HealthEconomics.Com (2018). Available at: https://www.healtheconomics.com/industry-news/healtheconomics-com-scientist-com-partner-on-rwe-heor-initiative.

, , , , , , , , , ,

No Comments

Building Trust In Real World Evidence – From Regulators To Patients

Bill Fox
Chief Strategist for Global Healthcare, Life Sciences, and Insurance
MarkLogic

 

 

In a climate of growing consumer distrust for companies that have access to their personal information, organizations that generate real world evidence must join the likes of financial services institutions and the government to ensure that the sensitive data in their charge is well governed, selectively accessible, and highly secure.


 

Real world evidence (RWE) is here to stay. And it brings with it a world of possibility—and vulnerability. As value-based reimbursement slowly displaces fee for service, payers and providers are under mounting pressure to deliver better patient outcomes at less cost. This, in turn, increases the burden on life sciences companies to not only demonstrate the effectiveness and safety of their products to the FDA through the traditional clinical trial process, but to also show evidence of their product’s overall value to patient health and total cost of care when the drug gets out in into the real world. RWE can play a crucial role in fulfilling the requirements of each of these stakeholders, with life sciences companies having additional interest in leveraging RWE to expedite market access for their products.

Historically, available evidence on pharmaceutical and medical device products has come from tightly-controlled clinical trials and is delivered to the FDA by the product’s sponsor. However, with increasing insight into the limitations of clinical trials in predicting a product’s safety and efficacy in wider, unstudied populations, the FDA has come to recognize that an abundance of product data is routinely collected via doctor visits, insurance claims, device registries, wearable technology, and even social media channels. And, though this real world data may not have the same data quality and bias controls as data collected in clinical trials, high-quality real world data (RWD) sources can dramatically enhance understanding of both the benefits and adverse effects of a product over its lifecycle—in everyday use across larger demographics.

 


“We need to close the evidence gap between the information we use to make FDA’s decisions and the evidence increasingly used by the medical community, by payers, and by others charged with making healthcare decisions”1

– Scott Gottlieb, FDA Commissioner


 

Further paving the way for real world evidence initiatives, the 21st Century Cures Act authorized $6.3 billion in funding to expedite the process by which new drugs and devices reach approval. The bill incentivizes life sciences companies to invest in data strategies that supplement traditional clinical, and pragmatic trials, and to potentially support FDA approval of new indications for previously approved drugs.

 

AVOIDING RISKS IN REAL WORLD EVIDENCE DEVELOPMENT

But, for all of its clear advantages and widespread support, the process of turning data from varied sources—with varying degrees of quality and lineage—into real world evidence also opens the door to a multitude of data quality, governance, and security issues that must be addressed in order to protect the integrity of the evidence produced.

 

Click to see a larger image.

 

DATA GOVERNANCE AND LINEAGE

In the wake of the recent data privacy fiasco in which 87 million unsuspecting Facebook users had their data unknowingly collected by a political firm, Cambridge Analytica, my colleague, David Gorbet, authored an article, Don’t Let a Data Debacle Like Facebook’s Happen at Your Company, on Entrepreneur.com outlining key lessons that every organization should learn from the recent debacle that has wrecked consumer confidence in the social media giant.

Data governance challenges should likewise weigh heavily on the minds of RWE generators responsible for safeguarding mass quantities of potentially sensitive data. To start with, repurposing of routine medical data for additional analyses often requires data cleaning and cross-referencing. These techniques can confirm the data’s internal consistency and identify missing values, but they cannot determine its accuracy and authenticity. How do you ensure accountability in your real world data when the data is sourced from many different silos, each with its own notions of data governance? Comparing data from traditional clinical research, or pragmatic trials, to source documents through audits (i.e., external consistency) is an essential additional step in verifying the accuracy and completeness of the data. This type of verification is important for real world data intended for use in regulatory analyses. And speaking of regulations, another significant challenge in working with real world data is posed by regulations regarding patient privacy and confidentiality.

HIPAA requires healthcare entities and their business associates to protect the privacy of patient information. The sharing of healthcare data between departments and organizations is often frustrated by the need to protect this data. To work within these confines, or regulations, data scientists are forced to wrangle the data to meet requirements for de-identification. Attempts to “de-identify” real world data in this manner can obfuscate it to the point that it loses its value. And in certain situations, as in the case of the strict data residency and sovereignty laws of some European countries, researchers are altogether prohibited from moving or sharing any patient data.

In many traditional database systems, data must undergo a number of separate transformation processes before it can be loaded into the database. These processes can lead to data quality disaster when a user sees a value from the database but is not clear where it came from. Was the value part of the original record? Or, was it added in transformation Step 2B? It can quickly become impossible to make heads or tails of the lineage and therefore the reliability of the data.

Tracing data lineage becomes much easier when data is loaded as is, while maintaining all its original metadata and schema, and transformation processes are performed against a canonical version of the data (while maintaining the original data unchanged), instead of having to perform multiple transformation steps before the data is ingested into the database. In this way, data scientists can see both the original data and the transformed data—making the enrichment and harmonization process much more transparent.1

 

MASTER DATA MANAGEMENT

For RWE, a consistent and accurate view of real world data is critical for hypothesis testing and analysis. However, when data is spread across disparate silos, it is difficult and costly to ascertain what the data means, whether it’s correct, how it relates to other data, and whether or not it’s secure. The main objective of master data management (MDM) is to provide a single, unified source of truth that sheds light on all of this ambiguity. This will prevent users from using overlapping, and possibly invalid or inconsistent, versions of data. But, MDM can prove a challenging undertaking. The projects are commonly large, costly and can take years to execute—if they succeed at all (and most don’t).

Without MDM, data silos and duplicate copies of data make it nearly impossible to secure and track the use of your real world data—increasing the possibility of breaches and exposure of sensitive information. Federation and warehousing with relational technology have proven too costly and brittle to solve these master data problems at scale. To protect their data, organizations need a better approach to MDM.

 

ENSURING DATA SECURITY

At this very moment, hackers are tirelessly searching and probing for vulnerabilities in the networks of organizations across the healthcare ecosystem. Their objective is a simple one: to acquire the protected health information (PHI) of patients and consumers, which, according to Becker’s is 10-20 times more valuable than credit card information. Regulated by HIPAA to protect the privacy of individuals, the theft of PHI can jeopardize consumer privacy, reputation, and identity—as well as patient trust in the organization that failed to keep their private data safe. Despite worldwide security spending expected to reach $170 billion by 2020—cyber attacks, data breaches, and the unsanctioned use of consumer data will continue to occur at an alarming rate.

Hospital networks, biotech, pharmaceutical, and medical device manufacturers all are vulnerable:

  • Data generated by clinical and pragmatic trials present risks on the level of patient privacy, and to the competitive objectives of the company
  • Organizational intelligence and trade secrets related to the discovery and production of complex drugs
  • Drug pricing and promotional information. Especially important in the face of budgetary pressures to ensure better patient outcomes while reducing healthcare costs2

As a former Deputy Chief of Economic and Cyber Crime at the Philadelphia District Attorney’s Office, and Special Assistant U.S. Attorney, I’ve been investigating, prosecuting and thinking about data security for 20 years. With the increase in inappropriate data sharing, and cyber attacks growing in sophistication, it’s clear to me that more vigilant methods must be employed to protect and govern the use of real world data assets.

 

PROTECT YOUR DATA AND YOUR REPUTATION

Traditional databases and traditional data security thinking focused on building walls around the network that would protect the data from outsiders, and lacked granular access controls offering too many all-or-none data access. This traditional cyber methodology is no longer sufficient to protect against modern threats to data security. Today’s RWE-generating organizations need the ability to clearly define who can see what data at the most granular level. Exposure of PHI, even to valid application users, may violate privacy regulations and put patient and consumer data at unnecessary risk. Controlling data access and security at the database-level addresses these risks more effectively and helps prevents exploitation of application or network flaws that may disclose sensitive data.

With security features that allow for policy-based management of how data is protected and exported in the database, an Enterprise NoSQL database platform can enable organizations to safeguard patient data with capabilities such as:

  • Advanced encryption that protects data from hackers and insider threats using standards-based cryptography, advanced key management, and granular separation of duties.
  • Redaction features that eliminate exposure of sensitive information by removing specifics to prevent sensitive data leaks.
  • Element-level security. This allows specific information to be hidden from particular users, providing an even more granular level of security enforced in the database.

In an environment of increasing cyber threat and sliding-scale ethics around the use of personal data by some companies entrusted with it—trust is at an all-time premium for organizations engaged in RWE generation. Developing real world evidence on an agile technology platform grounded in enterprise reliability and government-grade security can reduce time to insight while strengthening data governance—and waning consumer confidence.

 

Download this free whitepaper to learn more about The Opportunity of Real Word Data, or contact MarkLogic to learn how other life sciences organization are securely and efficiently accelerating their real world evidence initiatives.

, , , , , , ,

No Comments